KR890008113A - 퀴녹살린 화합물 및 이의 제조방법 및 용도 - Google Patents

퀴녹살린 화합물 및 이의 제조방법 및 용도 Download PDF

Info

Publication number
KR890008113A
KR890008113A KR1019880014744A KR880014744A KR890008113A KR 890008113 A KR890008113 A KR 890008113A KR 1019880014744 A KR1019880014744 A KR 1019880014744A KR 880014744 A KR880014744 A KR 880014744A KR 890008113 A KR890008113 A KR 890008113A
Authority
KR
South Korea
Prior art keywords
halogen
compound
hydrogen
formula
alkyl
Prior art date
Application number
KR1019880014744A
Other languages
English (en)
Other versions
KR970011279B1 (ko
Inventor
호노레 타게
자콥센 포울
엘멜룬트 니엘센 플레밍
내룸 라르즘
Original Assignee
외르겐 부스 라센
에이/에스 페로산
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from DK586287A external-priority patent/DK586287D0/da
Priority claimed from DK142288A external-priority patent/DK142288D0/da
Application filed by 외르겐 부스 라센, 에이/에스 페로산 filed Critical 외르겐 부스 라센
Publication of KR890008113A publication Critical patent/KR890008113A/ko
Application granted granted Critical
Publication of KR970011279B1 publication Critical patent/KR970011279B1/ko

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D241/00—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
    • C07D241/36—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings condensed with carbocyclic rings or ring systems
    • C07D241/38—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings condensed with carbocyclic rings or ring systems with only hydrogen or carbon atoms directly attached to the ring nitrogen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D241/00—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
    • C07D241/36—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings condensed with carbocyclic rings or ring systems
    • C07D241/38—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings condensed with carbocyclic rings or ring systems with only hydrogen or carbon atoms directly attached to the ring nitrogen atoms
    • C07D241/40—Benzopyrazines
    • C07D241/44—Benzopyrazines with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the hetero ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D241/00—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
    • C07D241/36—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings condensed with carbocyclic rings or ring systems
    • C07D241/50—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings condensed with carbocyclic rings or ring systems with hetero atoms directly attached to ring nitrogen atoms
    • C07D241/52—Oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Steroid Compounds (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicinal Preparation (AREA)

Abstract

내용 없음

Description

퀴녹살린 화합물 및 이의 제조방법 및 용도
본 내용은 요부공개 건이므로 전문내용을 수록하지 않았음

Claims (10)

  1. 일반식(Ⅰ)의 퀴녹살린 화합물.
    상기식에서 R1은 임의로 하이드록시, 프로밀, 카복시, 카복실 에스테르, 아미드 또는 아민으로 치환될 수있는 C1-12-알킬 ; 또는 C3-8-시클로알킬, 아릴 또는 아르알킬이고 ; R6은 수소, 할로겐, CN, CF3, NO2또는 OR'이며, R5, R7및 R8은 수소이고 ; 단 R1이 CH3일 경우에 R6은 CF3, OCH3, NO2, Cl 또는 Br이 아니거나 ; R6및 R7은 독립적으로 NO2, 할로겐 CN, CF3또는 OR'이고, R=및 R8은 각각 수소이거나 ; R5및 R6은 함께는, 할로겐, NO2, CN, CF3또는 OR'로 치환될 수 있는 추가 융합된 방향족환을 형성하고, R7및 R8은 독립적으로 수소, 할로겐 CN, CF3, NO2또는 OR'이거나 ; R7및 Rx은 함께는 할로겐 NO2, CN, CF3또는 OR'로 치환될 수 있는 추가 융합된 방향족환을 형성하고, R5및 R6은 독립적으로 수소, 할로겐, CN, CF3, NO2또는 OR'이며 ; R'은 C1-4-알킬이다.
  2. 제 1 항에 있어서, 1-시클로헥실-6-니트로 퀴녹살린-2,3(1H,4H)-디온인 화합물.
  3. 제 1 항에 있어서, 1-벤질-6-니트로퀴녹살린-2,3(1H,4H)-디온인 화합물.
  4. 제 1 항에 있어서, 4-메틸벤조[f]퀴녹살린-2,3(1H,4H)-디온인 화합물.
  5. 제 1 항에 있어서, 1-시클로핵실-7-클로르퀴녹살린-2,3(1H,4H)-디온인 화합물.
  6. 활성성분으로서 제 1 항에 따른 퀴녹살린 화합물 또는 약제학적으로 허용되는 이의 염 및 약제학적으로 허용되는 담체를 함유함을 특징으로 하는 약제학적 조성물.
  7. 제 6 항에 있어서, 활성 화합물 약 50 내지 200mg을 함유하는 경구 투여 단위 형태의 약제학적 조성물.
  8. 신경억제제, 특히 퀴스퀼레이트 길항제로서 유효한 양의 일반식(Ⅰ)의 화합물을 이를 필요로 하는 환자에게 투여하는 단계를 특징으로하여, 환자에 있어서, 흥분성 신경전달제 및 특히 퀴스퀼레이트 수용체의 기능항진과 관련된 증상을 치료하는 방법.
    상기식에서, R1은 임의로 하이드록시, 포르밀, 카복시, 복실에스테르, 아미드 또는 아민으로 치환될 수 있는 C1-12-알킬 ; 또는 C3--시클로알킬, 아릴 또는 아르알킬이고 ; R6은 수소, 할로겐 CN, CF3, NO2또는 OR'이며, R5, R7및 R8은 수소이거나 ; R6및 R7은 독립적으로 NO2, 할로겐, CN, CF3또는 OR'이고, R5및 R8은 각각 수소이거나 ; R5및 R6은 함께는, 할로겐, NO2, CN, CF3또는 OR'로 치환될 수 있는 추가융합된 방향족환을 형성하고, R7및 R8은 독립적으로 수소, 할로겐, CN, CF3, NO2또는 OR'이거나 ; R7및 R8은 함께는 할로겐, NO2, CN, CF3, 또는 OR'로 치환될 수 있는 추가 융합된 방향족환을 형성하고, R5및 R6은 독립적으로 수소, 할로겐, CN, CF3, NO2또는 OR'이며, R'은 C1-t-알킬이다.
  9. 제 1 항에 있어서, 신경억제제로서 사용되는 퀴녹살린 화합물.
  10. a) 일반식(Ⅱ)의 화합물을 옥살레이트 또는 이의 반응성 유도체와 반응시켜 일반식(Ⅰ)의 화합물을 형성하거나, b) 일반식(Ⅲ)의 화합물을 니트로화시켜 일반식(Ⅰ)의 화합물을 형성하거, c) 일반식(Ⅳ)의 화합물을 환원시켜 일반식(Ⅰ)의 화합물을 형성하거나 d) 일반식(Ⅴ)의 화합물을 환원시켜 일반식(Ⅰ)에 따른 화합물을 제조하는 방법.
    상기식에서, R1, R2, R6, R7및 R8은 제 1 항에서의 정의한 바와 같고, 단 일반식(Ⅲ)에서, R5, R6, R7및 R8중의 하나 이상은 수소이고, 다른 라디칼은 제 1 하에서 정의한 바와 같으며 ; 일반식(Ⅳ)에서, R5, R6, R7및 R8중의 하나 이상은 니트로이고, 다른 라디칼은 제 1 항에서 정의한 바와 같다.
    ※ 참고사항 : 최초출원 내용에 의하여 공개하는 것임.
KR1019880014744A 1987-11-10 1988-11-10 퀴녹살린 화합물, 이의 제조방법 및 이를 함유하는 약제학적 조성물 KR970011279B1 (ko)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
DK586287A DK586287D0 (da) 1987-11-10 1987-11-10 Quinoxalinforbindelser, deres fremstilling og anvendelse
DK5862/87 1987-11-10
DK1422/88 1988-03-16
DK142288A DK142288D0 (da) 1988-03-16 1988-03-16 Quinoxalinforbindelser, deres fremstilling og anvendelse

Publications (2)

Publication Number Publication Date
KR890008113A true KR890008113A (ko) 1989-07-08
KR970011279B1 KR970011279B1 (ko) 1997-07-09

Family

ID=26065733

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1019880014744A KR970011279B1 (ko) 1987-11-10 1988-11-10 퀴녹살린 화합물, 이의 제조방법 및 이를 함유하는 약제학적 조성물

Country Status (16)

Country Link
US (2) US4948794A (ko)
EP (1) EP0315959B1 (ko)
JP (1) JP2721520B2 (ko)
KR (1) KR970011279B1 (ko)
AT (1) ATE102192T1 (ko)
AU (1) AU618766B2 (ko)
CA (1) CA1321587C (ko)
DE (1) DE3888093T2 (ko)
ES (1) ES2061606T3 (ko)
FI (1) FI100181B (ko)
IE (1) IE64320B1 (ko)
IL (1) IL88155A0 (ko)
NO (2) NO179551C (ko)
NZ (1) NZ226916A (ko)
PH (1) PH25103A (ko)
PT (1) PT88964B (ko)

Families Citing this family (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NO179551C (no) * 1987-11-10 1996-10-30 Novo Nordisk As Analogifremgangsmåte for fremstilling av terapeutisk virksomme kinoxalinforbindelser
DK715888D0 (da) * 1988-12-22 1988-12-22 Ferrosan As Quinoxalinforbindelser, deres fremstilling og anvendelse
DK716188D0 (da) * 1988-12-22 1988-12-22 Ferrosan As Quinoxalinforbindelser, deres fremstilling og anvendelse
DK69790D0 (da) * 1990-03-16 1990-03-16 Novo Nordisk As Heterocykliske forbindelser, deres fremstilling af anvendelse
DK0556393T3 (da) * 1990-11-06 2000-10-16 Yamanouchi Pharma Co Ltd Tilkondenseret pyrazinderivat
PT99864B (pt) 1990-12-21 1999-06-30 Schering Ag Processo para a preparacao de novas composicoes farmaceuticas contendo antagonistas de receptor de quisqualato
DK73091D0 (da) * 1991-04-22 1991-04-22 Novo Nordisk As Quinoxalinforbindelser, deres fremstilling og anvendelse
US5153196A (en) * 1991-06-05 1992-10-06 Eli Lilly And Company Excitatory amino acid receptor antagonists and methods for the use thereof
US5196421A (en) * 1991-06-05 1993-03-23 Eli Lilly And Company Excitatory amino acid receptor antagonists in methods for the use thereof
DK177191D0 (da) * 1991-10-23 1991-10-23 Novo Nordisk As Heterocyclic compounds and their preparation and use
PT101004B (pt) * 1991-10-26 1999-10-29 Schering Ag Derivados da quinoxalina, processo para a sua preparacao e composicoes farmaceuticas que os contem
US6057304A (en) 1992-10-26 2000-05-02 Schering Aktiengesellschaft Quinoxaline-phosphonic acid derivatives
DE4217952A1 (de) * 1992-05-30 1993-12-02 Basf Ag Chinoxalin-2,3(1H,4H)-dione
EP0647137B1 (en) * 1992-06-22 2008-08-13 The Regents Of The University Of California Glycine receptor antagonists and the use thereof
FR2696466B1 (fr) * 1992-10-02 1994-11-25 Rhone Poulenc Rorer Sa Dérivés de 5H,10H-imidazo[1,2-a]indeno[1,2-e]pyrazine-4-one, leur préparation et les médicaments les contenant.
DK12293D0 (da) * 1993-02-02 1993-02-02 Novo Nordisk As Heterocykliske forbindelser og deres fremstilling og anvendelse
DE4314592A1 (de) * 1993-04-28 1994-11-03 Schering Ag Benzo(f)chinoxalindionderivate, deren Herstellung und Verwendung in Arzneimitteln
IL109397A0 (en) * 1993-04-28 1994-07-31 Schering Ag Quinoxalinedione derivatives, processes for the preparation thereof and pharmaceutical compositions containing the same
US5631373A (en) * 1993-11-05 1997-05-20 State Of Oregon, Acting By And Through The Oregon State Board Of Higher Education, Acting For And On Behalf Of The Oregon Health Sciences University And The University Of Oregon, Eugene Oregon Alkyl, azido, alkoxy, and fluoro-substituted and fused quinoxalinediones
DE4340045A1 (de) * 1993-11-24 1995-06-01 Basf Ag Neue Chinoxaline und Arzneimittel daraus
AU688459B2 (en) * 1994-04-08 1998-03-12 Shionogi & Co., Ltd. Oxopyridinylquinoxaline derivative
DE4428152A1 (de) * 1994-06-22 1996-01-04 Basf Ag Neue Amido-chinoxalindione, ihrer Herstellung und Verwendung
US5597922A (en) * 1994-07-29 1997-01-28 State Of Oregon, Acting By And Through The Oregon State Board Of Higher Education, Acting For And On Behalf Of The Oregon Health Sciences University And The University Of Oregon Glycine receptor antagonist pharmacophore
DE4436852A1 (de) * 1994-10-14 1996-04-18 Basf Ag Pyrrolyl-tetrahydrobenzochinoxalindione, ihre Herstellung und Verwendung
DE19521058A1 (de) * 1995-06-09 1996-12-12 Basf Ag Verfahren zur Herstellung von Aromaten enthaltenden Polyetherpolyolen
DE19545251A1 (de) * 1995-11-24 1997-05-28 Schering Ag Neue Chinoxalindionderivate, deren Herstellung und Verwendung in Arzneimitteln
DE19624808A1 (de) 1996-06-21 1998-01-02 Basf Ag Pyrrolylchinoxalindione, ihre Herstellung und Verwendung
SK282548B6 (sk) * 1996-10-24 2002-10-08 Novartis Ag Substituované aminoalkánfosfónové kyseliny, spôsob ich prípravy, farmaceutické prostriedky, ktoré ich obsahujú, a ich použitie
HUP0001311A3 (en) * 1997-02-18 2001-07-30 American Home Products Corp Ma 5-aminoalkoxy-1,4-dihydroquinoxaline-2,3-diones being dopamine agonists and pharmaceutical compositions containing them
US5922715A (en) * 1997-02-18 1999-07-13 American Home Products Corporation 5-aminoalkoxy-1, 4-dihydroquinoxaline-2, 3-diones
JP4707261B2 (ja) * 2001-05-15 2011-06-22 日本エンバイロケミカルズ株式会社 キノキサリン系化合物および工業用殺菌組成物
WO2005000795A2 (en) * 2003-06-10 2005-01-06 Smithkline Beecham Corporation Aniline derivatived androgen-, glucocorticoid-, mineralcorticoid- and progesterone- receptor modulators
EP2338492A1 (en) 2009-12-24 2011-06-29 Universidad del Pais Vasco Methods and compositions for the treatment of alzheimer
WO2012014910A1 (ja) 2010-07-29 2012-02-02 日本ケミファ株式会社 Ｐ２ｘ４受容体拮抗剤
EP3427729A1 (en) 2017-07-13 2019-01-16 Paris Sciences et Lettres - Quartier Latin Probenecid for use in treating epileptic diseases, disorders or conditions
US10890033B1 (en) 2017-12-10 2021-01-12 Watson, Incorporated Kelly bar with locking feature, related system and method

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3431111A (en) * 1963-06-10 1969-03-04 Eastman Kodak Co Cyanine dyes
US3992378A (en) * 1973-12-26 1976-11-16 Eli Lilly And Company Fluoralkyl quinoxadinediones
EP0008864A1 (en) * 1978-08-15 1980-03-19 FISONS plc Pyridopyrazine and quinoxaline derivatives, processes for their preparation, and pharmaceutical compositions containing them
EP0030795A3 (en) * 1979-12-06 1981-09-09 Imperial Chemical Industries Plc Quinoxaline derivatives, processes therefor, pharmaceutical compositions, and benzene derivatives
EP0039920B1 (en) * 1980-05-09 1984-07-25 Usv Pharmaceutical Corporation Triazaloquinoxalin-1,4-diones
US4659713A (en) * 1984-10-01 1987-04-21 International Minerals & Chemical Corp. Quinoxalinedione compounds useful for controlling coccidiosis
US4812458A (en) * 1986-09-16 1989-03-14 A/S Ferrosan 6,7-disubstituted-2,3-dihydroxyquinoxaline compounds, pharmaceutical compositions thereof, and their use as neuroleptics
DK146787A (da) * 1987-03-23 1988-09-24 Ferrosan Heterocykliske forbindelser, deres fremstilling og anvendelse
NO179551C (no) * 1987-11-10 1996-10-30 Novo Nordisk As Analogifremgangsmåte for fremstilling av terapeutisk virksomme kinoxalinforbindelser

Also Published As

Publication number Publication date
JP2721520B2 (ja) 1998-03-04
NO884729D0 (no) 1988-10-24
NO179551C (no) 1996-10-30
IL88155A0 (en) 1989-06-30
EP0315959A2 (en) 1989-05-17
IE64320B1 (en) 1995-07-26
PT88964A (pt) 1988-12-01
DE3888093D1 (de) 1994-04-07
FI100181B (fi) 1997-10-15
EP0315959B1 (en) 1994-03-02
ES2061606T3 (es) 1994-12-16
AU618766B2 (en) 1992-01-09
NO307252B1 (no) 2000-03-06
PT88964B (pt) 1993-02-26
NO884729L (no) 1989-05-11
CA1321587C (en) 1993-08-24
FI885151A0 (fi) 1988-11-09
NO963412L (no) 1989-05-11
PH25103A (en) 1991-02-19
NZ226916A (en) 1991-01-29
IE883209L (en) 1989-05-10
ATE102192T1 (de) 1994-03-15
FI885151A (fi) 1989-05-11
NO179551B (no) 1996-07-22
KR970011279B1 (ko) 1997-07-09
JPH01153680A (ja) 1989-06-15
DE3888093T2 (de) 1994-06-09
AU2494988A (en) 1989-05-11
US4948794A (en) 1990-08-14
US5026704A (en) 1991-06-25
EP0315959A3 (en) 1989-12-27

Similar Documents

Publication Publication Date Title
KR890008113A (ko) 퀴녹살린 화합물 및 이의 제조방법 및 용도
KR880011125A (ko) 헤테로 싸이클릭 화합물, 그의 제조방법 및 용도
KR960007545A (ko) 합성 흥분성 아미노산
EA200000592A1 (ru) Азаполициклические соединения, конденсированные с арилом
EA200100203A1 (ru) Производные 4,4-биарилпиперидина с активностью в отношении опиоидных рецепторов
FI942910A (fi) Uusia fosfonimeripihkahappojohdannaisia, menetelmä niiden valmistamiseksi ja näitä yhdisteitä sisältäviä lääkkeitä
EA200300718A1 (ru) Производные 3-индолина, которые могут применяться при лечении психиатрических и неврологических расстройств
ES2112386T3 (es) Agentes terapeuticos para uso en el tratamiento de la enfermedad de parkinson.
BR0016951A (pt) Derivado de fenilpiperazinil, composto, composição farmacêutica, uso do mesmo, método de tratamento
ATE125808T1 (de) Indolederivate und ihre verwendung als serotonin- antagoniste.
KR900018112A (ko) 흥분성 아미노산 길항제
EE02950B1 (et) Metüleenbisfosfoonhappe esteramiidderivaadid, meetod nende valmistamiseks ja farmatseutiline kompositsioon
IL134894A (en) 2-substituted-1,3,4,5-tetrahydro-2h-gamma-carbolines, their preparation and pharmaceutical compositions containing them
ES2089255T3 (es) N-(ariloxialquil)heteroaril-8-azabiciclo(3.2.1)octanos, compuestos intermedios y un procedimiento para su preparacion y su uso como medicamentos.
KR910000607A (ko) 새로운 에스테르
ATE204278T1 (de) Serotoninergische ergolin derivate
AU2502997A (en) New 2,3-benzodiazepine derivatives, their production and use as pharmaceutical agents
KR960029312A (ko) N-아릴알킬페닐아세트아미드 유도체와 그의 제조방법
ATE31929T1 (de) Derivate von 9-oxalysergsaeure, ihre salze, verfahren und zwischenprodukte zu ihrer herstellung, verwendung als arzneimittel und diese enthaltende zusammensetzungen.
ATE16383T1 (de) Neue heteroaryloxypropanolamine, verfahren zu ihrer herstellung und diese verbindungen enthaltende arzneimittel.
KR100215609B1 (ko) 퀴노질린 유도체를 포함하는 식욕증진제로서 유용한 약제학적 조성물
AR011136A1 (es) Compuesto derivado 4-aminoalcoxi-1h-benzoimidazoles, composicion farmaceutica que lo contiene y el uso del mismo para la fabricacion de unmedicamento
NO984699D0 (no) Fenyletanolamino-tetralinkarboks-amid-derivater
FR2633292B1 (fr) Nouveaux derives de la 20,21-dinoreburnamenine substitues en 15 par un groupement amine, leur procede de preparation et les intermediaires ainsi obtenus, leur application comme medicaments et les compositions pharmaceutiques les reenfermant
KR920011491A (ko) 헥사히드로-8-히드록시-2, 6-메타노-2h-퀴놀리진-3(4h)-온 및 관련 화합물의 특정 에스테르를 함유하는 인식 장애 치료용 제약 조성물

Legal Events

Date Code Title Description
A201 Request for examination
E902 Notification of reason for refusal
G160 Decision to publish patent application
E701 Decision to grant or registration of patent right
GRNT Written decision to grant
FPAY Annual fee payment

Payment date: 20000517

Year of fee payment: 4

LAPS Lapse due to unpaid annual fee